DePuy Synthes commenced U.S. launch of TFNA Augmentation, which the company claims to be the first polymethylmethacrylate (PMMA) cement system with specific trauma device indications, offered exclusively for use with the TFN-ADVANCED® Proximal Femoral Nail (TFNA) to address poor bone quality.
When used with the TFNA nail, TFNA Augmentation is intended to reduce the risk of cut-out—a loss of implant stability in the bone—and provide enhanced implant fixation.
DePuy’s TFNA nail debuted in 1Q15, and has since remained a consistently-cited supporter of the company’s trauma sales.
DePuy Synthes commenced U.S. launch of TFNA Augmentation, which the company claims to be the first polymethylmethacrylate (PMMA) cement system with specific trauma device indications, offered exclusively for use with the TFN-ADVANCED® Proximal Femoral Nail (TFNA) to address poor bone quality.
When used with the TFNA nail, TFNA Augmentation is...
DePuy Synthes commenced U.S. launch of TFNA Augmentation, which the company claims to be the first polymethylmethacrylate (PMMA) cement system with specific trauma device indications, offered exclusively for use with the TFN-ADVANCED® Proximal Femoral Nail (TFNA) to address poor bone quality.
When used with the TFNA nail, TFNA Augmentation is intended to reduce the risk of cut-out—a loss of implant stability in the bone—and provide enhanced implant fixation.
DePuy’s TFNA nail debuted in 1Q15, and has since remained a consistently-cited supporter of the company’s trauma sales.
Copy to clipboard 
